Zoetis Inc. Class A Common Stock (ZTS)
Stock · NYSE · Health Care
$79.39as of 10/16/2026
Price chart
Active signals
ZTS Signal Track Record
How signals performed across all stocks →What ZTS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 30 | -0.1% | 50% | September 8, 2026 |
| Bollinger Band Breakdown | 22 | -1.0% | 45% | August 7, 2026 |
| 200-Day Moving Average TouchActive now | 14 | -0.0% | 50% | June 2, 2025 |
| Bollinger Band BreakoutActive now | 12 | +0.8% | 58% | October 9, 2026 |
| Any 20-session window (baseline) | -1.0% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ZTS
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 14,500
- Website
- www.zoetis.com/
Fundamentals
- 1-day range
- $78.29$80.59
- Market cap
- $32.39B
- P/E (trailing)
- 12.43
- P/E (forward)
- 12.13
- EPS (trailing)
- $6.08
- Dividend yield
- 1.64%
- Beta
- 0.71
- Avg. volume
- 5.27M
- Ex-dividend date
- October 30, 2026
- Dividend pay date
- December 1, 2026
How Zoetis Inc. Class A Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
14 analyst ratings
Zoetis Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- ZTSZoetis Inc. Class A Common Stock$79.38▲ 1.22%Market cap $32.39BP/E 12.43$68.77$148.3
- RPRXRoyalty Pharma plc Class A Ordinary Shares$60.96▲ 2.25%Market cap $32.97BP/E 41.57$35.23$64.38
- ALNYAlnylam Pharmaceuticals Inc. Common Stock$231.83▼ 0.94%Market cap $28.92BP/E 37.17$197.81$495.55
- INSMInsmed Incorporated Common Stock$96.27▼ 2.96%Market cap $28.73BP/E —$90.39$212.75
- ONCBeOne Medicines Ltd. American Depositary Shares$369.06▼ 1.34%Market cap $36.67BP/E 61.27$205.51$319.24
- ROIVRoivant Sciences Ltd. Common Shares$33.53▼ 1.50%Market cap $25.38BP/E —$15.9$42.5
- TEVATeva Pharmaceutical Industries Limited American Depositary Shares$41.5▲ 0.95%Market cap $40.56BP/E 68.57$6,207$12,990
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ZTS Zoetis Inc. Class A Common Stock | $32.39B | 12.43 | $79.38 | ▲ 1.22% | $68.77$148.3 |
| RPRX Royalty Pharma plc Class A Ordinary Shares | $32.97B | 41.57 | $60.96 | ▲ 2.25% | $35.23$64.38 |
| ALNY Alnylam Pharmaceuticals Inc. Common Stock | $28.92B | 37.17 | $231.83 | ▼ 0.94% | $197.81$495.55 |
| INSM Insmed Incorporated Common Stock | $28.73B | — | $96.27 | ▼ 2.96% | $90.39$212.75 |
| ONC BeOne Medicines Ltd. American Depositary Shares | $36.67B | 61.27 | $369.06 | ▼ 1.34% | $205.51$319.24 |
| ROIV Roivant Sciences Ltd. Common Shares | $25.38B | — | $33.53 | ▼ 1.50% | $15.9$42.5 |
| TEVA Teva Pharmaceutical Industries Limited American Depositary Shares | $40.56B | 68.57 | $41.5 | ▲ 0.95% | $6,207$12,990 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Goldman Sachs Initiates Coverage On Zoetis with Neutral Rating, Announces Price Target of $74benzinga · 10/16/2026
- Zoetis (ZTS) Outpaces Stock Market Gains: What You Should KnowYahoo · 10/9/2026
- A Once-in-a-Decade Opportunity: 2 Magnificent Dividend Stocks Down 34% to 52% I'm Buying Right NowYahoo · 10/9/2026
- 10 Health Care Stocks Whale Activity In Today’s SessionBenzinga · 10/9/2026
- Zoetis (NYSE:ZTS): A Quality Dividend Stock for Income Investors With Room to GrowChartMill · 10/9/2026
- Zoetis Declares Fourth Quarter 2026 DividendYahoo · 10/8/2026
- Zoetis (ZTS) Says Study Shows Simparica Trio Outperformed A Rival On Resistant HeartwormYahoo · 10/8/2026
- Is it the Right Time to Add Phibro Stock to Your Portfolio?Yahoo · 10/8/2026
- Neogen Corporation: Promising Recurring Demand With Food SafetySeekingAlpha · 10/8/2026
Insider Activity
Insider Actions →- FULLER JULIE · September 30, 2026 · Option Exercise799
- FULLER JULIE · September 30, 2026 · Tax Withholding274 @ $69.83
- Mark Stetter · September 17, 2026 · Grant342 @ $73.02
- James Saccaro · August 31, 2026 · Grant81.1K
- Frank A. Damelio · August 7, 2026 · Gift6.7K
- Kristin C. Peck · July 10, 2026 · Grant616 @ $26.22
- Joseph Wetteny · July 10, 2026 · Grant363 @ $26.22
- Keith Sarbaugh · July 10, 2026 · Grant260 @ $26.22
- Nayak Abhay U · July 10, 2026 · Grant215 @ $26.22
- Kevin Esch · July 10, 2026 · Grant308 @ $26.22
- Rimma Driscoll · July 10, 2026 · Grant238 @ $26.22
- FULLER JULIE · July 10, 2026 · Grant315 @ $26.22
- Lagano Roxanne · July 10, 2026 · Grant315 @ $26.22
- Ferran Astorga Jeannette · July 10, 2026 · Grant45 @ $26.22
- Mark Stetter · June 18, 2026 · Grant318 @ $78.71
Institutional Ownership
March 31, 2026
- Total shares held
- 377.95M
- Total value held
- $43.21B
- Institutional holders
- 1575
- Unknown35.58M
- Unknown26.07M
- Unknown19.32M
- Unknown15.89M
- Unknown14.15M
- Unknown11.35M
- Unknown10.15M
- Unknown5.87M
- Unknown5.66M
- Unknown5.55M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Goldman Sachs initiates Zoetis coverage with Neutral rating
Goldman Sachs began covering Zoetis with a Neutral rating and a $74 price target. This follows recent guidance cuts that the market initially shrugged off, alongside a new board appointment. The stock currently trades near a key support level, with an RSI of 71.0 indicating strong recent momentum.
Goldman Sachs initiates Zoetis coverage with Neutral rating. Goldman Sachs began covering Zoetis with a Neutral rating and a $74 price target. This follows recent guidance cuts that the market initially shrugged off, alongside a new board appointment. The stock currently trades near a key support level, with an RSI of 71.0 indicating strong recent momentum.